AnaptysBio Q1 net loss $43.9M, cash $370M; Phase 2b data for ANB032 by YE2024, $50M royalty monetization

ANAPTYSBIO, INC

2024-Q1 EPS reported -$1.64 revenue$7,179,000

Q1 2024 net loss $43.9M ($1.64/share) vs $44.3M ($1.58/share) in Q1 2023; revenue $7.2M from Jemperli royalties.
Cash, cash equivalents, investments total $370.1M (excl. $50M monetization); cash runway through year-end 2026.
Phase 2b trial for ANB032 (BTLA agonist) in atopic dermatitis enrolling; top-line data expected by year-end 2024.
Phase 2b trial for rosnilimab (PD-1 agonist) in RA and Phase 2 trial in UC enrolling; top-line data mid-2025 and H1 2026.
Announced $50M capped non-recourse royalty monetization from Sagard for additional Jemperli royalties; positive Phase 3 imsidolimab results in GPP.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.99

ANAPTYSBIO, INC reported first quarter ended March 31, 2024 results: revenue $7.2 million.

Period: first quarter ended March 31, 2024
Revenue: $7.2 million
Result: reported results

Exact text from the filing

activities as well as a one-time non-operating cash payment of $10.9 million during the quarter. ◦ Reiterating cash runway through year-end 2026 • Collaboration revenue was $7.2 million for the three months ended March 31, 2024, compared to $1.4 million for the three months ended March 31, 2023. The change is due primarily to increased royalties

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

ANAPTYSBIO, INC filing history →

Source: SEC EDGAR

accession 0001370053-24-000026

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.